Enzo Biochem (NYSE: ENZ) may have some royalty payments coming |
 |
 |
| By M.E.Garza |
| Monday, 01 March 2010 10:17 |
|
It appears that Enzo Biochem (NYSE: ENZ) won its patent interference case against Chiron, now Bayer HealthCare LLC, which now makes Enzo Biochem the senior party. The implication of this news is far reaching for Enzo Biochem, given that Chiron has infringed on Enzo. The current sales on products that infringe are worth an estimated $100 million per year and if one assumes a mid-single digit royalty, that would be worth an estimated $5-7 million per year to Enzo Biochem for at least the next 17 years. Once news hits about this in a bigger way, then all bets are off. Just posting this in case some of our readers who like speculative trades can get ahead of it. Disclosure: Long ENZ BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
Free Phone Trade Alerts
